Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory impairment. Neuroinflammatory processes, mediated by glial and immune cells, contribute to neuronal damage. Emerging evidence implicates innate immune mechanisms, including trained immunity and cell trans-differentiation, in AD pathogenesis, though their roles remain unclear.
Objective
To investigate transcriptomic changes in the 3xTg-AD mouse model, focusing on trained immunity and cell trans-differentiation in disease mechanisms.
Methods
RNA-sequencing was performed on brain tissue (cortex plus hippocampus) from 11-month-old female 3xTg-AD and wild-type mice (n = 3/group). Differentially expressed genes (fold change > 1.5, p < 0.05) were identified and followed by bioinformatics and knowledge-based transcriptomic profiling. Public AD datasets were also analyzed.
Results
3xTg-AD mice exhibited 316 upregulated and 412 downregulated genes. Downregulated genes included those for blood-brain barrier protein, while upregulated genes related to cerebrospinal fluid. Increased expression of proinflammatory markers, as well as genes related to cell differentiation, proliferation, activation, and adhesion. Upregulation of genes associated with cell migration and trans-differentiation suggests a potential role for inflammation and cellular plasticity. Additionally, genes involved in inflammasome pathways, immunometabolism, and trained immunity were upregulated. Mechanistically, these genes were modulated by knockdown of trained immunity promoter SET-7, overexpression of trained immunity inhibitor IL-37, and knockout of inflammasome genes IL-1 receptor, caspase-1, and pattern recognition receptor CD36.
Conclusions
The finding underscore the potential role of trained immunity and cell trans-differentiation in AD, revealing a mechanistic framework in which danger-associated molecular patterns drive innate immune responses, inflammasome activation, and cell plasticity contribute to AD, offering therapeutic targets for neuroinflammation and cellular reprograming.
LeYGongWTiffanyHL, et al.Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci2001; 21: RC123.
6.
KoldamovaRPLefterovIMLefterovaMI, et al.Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry2001; 40: 3553–3560.
7.
MaezawaIJinLWWoltjerRL, et al.Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity. J Neurochem2004; 91: 1312–1321.
8.
RicciarelliRFedeleE. The amyloid cascade hypothesis in Alzheimer's disease: it's time to change our mind. Curr Neuropharmacol2017; 15: 926–935.
9.
OddoSCaccamoAShepherdJD, et al.Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron2003; 39: 409–421.
10.
DrummerCTSaaoudFShaoY, et al.Trained immunity and reactivity of macrophages and endothelial cells. Arterioscler Thromb Vasc Biol2021; 41: 1032–1046.
11.
SaaoudFLiuLXuK, et al.Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways. JCI Insight2023; 8: e158183.
12.
TeufelLUArtsRJWNeteaMG, et al.IL-1 family cytokines as drivers and inhibitors of trained immunity. Cytokine2022; 150: 155773.
13.
WuLXianXXuG, et al.Toll-like receptor 4: a promising therapeutic target for Alzheimer's disease. Mediators Inflamm2022; 2022: 7924199.
14.
MironJPicardCFrappierJ, et al.TLR4 Gene expression and pro-inflammatory cytokines in Alzheimer's disease and in response to hippocampal deafferentation in rodents. J Alzheimers Dis2018; 63: 1547–1556.
15.
JiangSMaphisNMBinderJ, et al.Proteopathic tau primes and activates interleukin-1beta via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep2021; 36: 109720.
16.
ShiJQShenWChenJ, et al.Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res2011; 1368: 239–247.
17.
SteelandSGorléNVandendriesscheC, et al.Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease. EMBO Mol Med2018; 10: e8300.
18.
FloresJNoëlAFoveauB, et al.Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model. Nat Commun2018; 9: 3916.
19.
KitazawaMChengDTsukamotoMR, et al.Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol2011; 187: 6539–6549.
20.
TeissierTBoulangerÉ. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Biogerontology2019; 20: 279–301.
21.
FangFYuQArancioO, et al.RAGE Mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity. Hum Mol Genet2018; 27: 1002–1014.
22.
KleinbergerGYamanishiYSuárez-CalvetM, et al.TREM2 Mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med2014; 6: 243–286.
23.
Chhibber-GoelJColeman-VaughanCAgrawalV, et al.γ-secretase activity is required for regulated intramembrane proteolysis of tumor necrosis factor (TNF) receptor 1 and TNF-mediated pro-apoptotic signaling. J Biol Chem2016; 291: 5971–5985.
24.
WangWYTanMSYuJT, et al.Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann Transl Med2015; 3: 136.
25.
VukicVCallaghanDWalkerD, et al.Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis2009; 34: 95–106.
26.
GitterBDCoxLMRydelRE, et al.Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc Natl Acad Sci U S A1995; 92: 10738–10741.
27.
SongDKImYBJungJS, et al.Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem2001; 76: 1326–1335.
28.
JonesRSMinogueAMConnorTJ, et al.Amyloid-β-induced astrocytic phagocytosis is mediated by CD36, CD47 and RAGE. J Neuroimmune Pharmacol2013; 8: 301–311.
29.
CartyMGuyCBowieAG. Detection of viral infections by innate immunity. Biochem Pharmacol2021; 183: 114316.
30.
Calvo-RodriguezMGarcía-RodríguezCVillalobosC, et al.Role of toll like receptor 4 in Alzheimer's disease. Front Immunol2020; 11: 1588.
31.
FialaMCribbsDHRosenthalM, et al.Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis2007; 11: 457–463.
32.
WangXLiYFNanayakkaraG, et al.Lysophospholipid receptors, as novel conditional danger receptors and homeostatic receptors modulate inflammation-novel paradigm and therapeutic potential. J Cardiovasc Transl Res2016; 9: 343–359.
33.
ClarkIAVisselB. Amyloid β: one of three danger-associated molecules that are secondary inducers of the proinflammatory cytokines that mediate Alzheimer's disease. Br J Pharmacol2015; 172: 3714–3727.
34.
YinYPastranaJLLiX, et al.Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci2013; 18: 638–649.
35.
YinYYanYJiangX, et al.Inflammasomes are differentially expressed in cardiovascular and other tissues. Int J Immunopathol Pharmacol2009; 22: 311–322.
36.
Meier-StephensonFSMeier-StephensonVCCarterMD, et al.Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites. Alzheimers Dement (N Y)2022; 8: e12283.
37.
ArshavskyYI. Alzheimer's disease: from amyloid to autoimmune hypothesis. Neuroscientist2020; 26: 455–470.
38.
D'AndreaMR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses2005; 64: 458–463.
39.
WeaverDF. Alzheimer's disease as an innate autoimmune disease (AD(2)): a new molecular paradigm. Alzheimers Dement2023; 19: 1086–1098.
40.
NgBYangFHustonDP, et al.Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol2004; 114: 1463–1470.
41.
BetrainsAStaelsFSchrijversR, et al.Systemic autoinflammatory disease in adults. Autoimmun Rev2021; 20: 102774.
42.
LiXWangLFangP, et al.Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation. J Biol Chem2018; 293: 11033–11045.
43.
XuKShaoYSaaoudF, et al.Novel knowledge-based transcriptomic profiling of lipid lysophosphatidylinositol-induced endothelial cell activation. Front Cardiovasc Med2021; 8: 773473.
44.
YangQSaaoudFLuY, et al.Innate immunity of vascular smooth muscle cells contributes to two-wave inflammation in atherosclerosis, twin-peak inflammation in aortic aneurysms and trans-differentiation potential into 25 cell types. Front Immunol2023; 14: 1348238.
45.
MonroyMAFangJLiS, et al.Chronic kidney disease alters vascular smooth muscle cell phenotype. Front Biosci (Landmark Ed)2015; 20: 784–795.
46.
LaiBWangJFagensonA, et al.Twenty novel disease group-specific and 12 new shared macrophage pathways in eight groups of 34 diseases including 24 inflammatory organ diseases and 10 types of tumors. Front Immunol2019; 10: 2612.
47.
JollerNLozanoEBurkettPR, et al.Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity2014; 40: 569–581.
48.
XuKYangWYNanayakkaraGK, et al.GATA3, HDAC6, and BCL6 regulate FOXP3+ Treg plasticity and determine Treg conversion into either novel antigen-presenting cell-like Treg or Th1-Treg. Front Immunol2018; 9: 45.
49.
ShaoYYangWYSaaoudF, et al.IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms. JCI Insight2021; 6: e152511.
50.
ZhangRXuKShaoY, et al.Tissue Treg secretomes and transcription factors shared with stem cells contribute to a Treg niche to maintain treg-ness with 80% innate immune pathways, and functions of immunosuppression and tissue repair. Front Immunol2020; 11: 632239.
51.
SaaoudFMartinezLLuY, et al.Chronic kidney disease transdifferentiates veins into a specialized immune-endocrine organ with increased MYCN-AP1 signaling. Cells2023; 12: 1482.
52.
LuYSunYSaaoudF, et al.ER Stress mediates Angiotensin II-augmented innate immunity memory and facilitates distinct susceptibilities of thoracic from abdominal aorta to aneurysm development. Front Immunol2023; 14: 1268916.
53.
FerrerLMMonroyAMLopez-PastranaJ, et al.Caspase-1 plays a critical role in accelerating chronic kidney disease-promoted neointimal hyperplasia in the carotid artery. J Cardiovasc Transl Res2016; 9: 135–144.
54.
WangFLiRZhangL, et al.Cell transdifferentiation: a challenging strategy with great potential. Cell Reprogram2023; 25: 154–161.
55.
ShaoYSaredyJYangWY, et al.Vascular endothelial cells and innate immunity. Arterioscler Thromb Vasc Biol2020; 40: e138–e152.
56.
ZhongCYangXFengY, et al.Trained immunity: an underlying driver of inflammatory atherosclerosis. Front Immunol2020; 11: 284.
57.
YinYLiXShaX, et al.Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol2015; 35: 804–816.
58.
LiXFangPLiY, et al.Mitochondrial reactive oxygen species mediate lysophosphatidylcholine-induced endothelial cell activation. Arterioscler Thromb Vasc Biol2016; 36: 1090–1100.
59.
ShaoYSaredyJXuK, et al.Endothelial immunity trained by coronavirus infections, DAMP stimulations and regulated by anti-oxidant NRF2 may contribute to inflammations, myelopoiesis, COVID-19 cytokine storms and thromboembolism. Front Immunol2021; 12: 653110.
60.
ZhangDFangPJiangX, et al.Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res2012; 111: 37–49.
61.
ZhangDJiangXFangP, et al.Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice. Circulation2009; 120: 1893–1902.
62.
JohnsonCDrummer IvCShanH, et al.A novel subset of CD95(+) pro-inflammatory macrophages overcome miR155 deficiency and may serve as a switch from metabolically healthy obesity to metabolically unhealthy obesity. Front Immunol2020; 11: 619951.
63.
XiongZSongJYanY, et al.Higher expression of Bax in regulatory T cells increases vascular inflammation. Front Biosci2008; 13: 7143–7155.
64.
XiongZYanYSongJ, et al.Expression of TCTP antisense in CD25(high) regulatory T cells aggravates cuff-injured vascular inflammation. Atherosclerosis2009; 203: 401–408.
65.
YangXF. Factors regulating apoptosis and homeostasis of CD4+CD25highFOXP3+ regulatory T cells are new therapeutic targets. Front Biosci2008; 13: 1472–1499.
66.
LuYSunYXuK, et al.Aorta in pathologies may function as an immune organ by upregulating secretomes for immune and vascular cell activation, differentiation and trans-differentiation-early secretomes may serve as drivers for trained immunity. Front Immunol2022; 13: 858256.
67.
ZhangRSaredyJShaoY, et al.End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression. Redox Biol2020; 34: 101460.
68.
NiDTangTLuY, et al.Canonical secretomes, innate immune caspase-1-, 4/11-gasdermin D non-canonical secretomes and exosomes may contribute to maintain Treg-Ness for Treg immunosuppression, tissue repair and modulate anti-tumor immunity via ROS pathways. Front Immunol2021; 12: 678201.
69.
XuKSaaoudFShaoY, et al.Early hyperlipidemia triggers metabolomic reprogramming with increased SAH, increased acetyl-CoA-cholesterol synthesis, and decreased glycolysis. Redox Biol2023; 64: 102771.
70.
YangXFYinYWangH. Vascular inflammation and atherogenesis are activated via receptors for PAMPs and suppressed by regulatory T cells. Drug Discov Today Ther Strateg2008; 5: 125–142.
71.
ChenYZhangJCuiW, et al.CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate. J Exp Med2022; 219: e20211314.
72.
DrummerCIVSaaoudFSunY, et al.Hyperlipidemia may synergize with hypomethylation in establishing trained immunity and promoting inflammation in NASH and NAFLD. J Immunol Res2021; 2021: 3928323.
73.
SaaoudFLuYXuK, et al.Protein-rich foods, sea foods, and gut microbiota amplify immune responses in chronic diseases and cancers - Targeting PERK as a novel therapeutic strategy for chronic inflammatory diseases, neurodegenerative disorders, and cancer. Pharmacol Ther2024; 255: 108604.
74.
HalleAHornungVPetzoldGC, et al.The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol2008; 9: 857–865.
75.
JungESSuhKHanJ, et al.Amyloid-β activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Syk-AMPK pathway. Aging Cell2022; 21: e13623.
76.
KitazawaMOddoSYamasakiTR, et al.Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci2005; 25: 8843–8853.
77.
KarchCMGoateAM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry2015; 77: 43–51.
78.
HuangTYXuH. Bringing order out of chaos: establishing an epistatic relationship between cd33 and trem2. neuron2019; 103: 747–749.
79.
FrostGRJonasLALiYM. Friend, foe or both? Immune activity in Alzheimer's disease. Front Aging Neurosci2019; 11: 337.
80.
GriciucATanziRE. The role of innate immune genes in Alzheimer's disease. Curr Opin Neurol2021; 34: 228–236.
81.
BaileyCCZhongGHuangIC, et al.IFITM-family proteins: the cell's first line of antiviral defense. Annu Rev Virol2014; 1: 261–283.
82.
HurJYFrostGRWuX, et al.The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease. Nature2020; 586: 735–740.
83.
LiYFHuangXLiX, et al.Caspase-1 mediates hyperlipidemia-weakened progenitor cell vessel repair. Front Biosci (Landmark Ed)2016; 21: 178–191.
84.
LiXFangPSunY, et al.Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells. Redox Biol2020; 28: 101373.
85.
ShaoYSaaoudFCornwellW, et al.Cigarette smoke and morphine promote Treg plasticity to Th17 via enhancing trained immunity. Cells2022; 11: 2810.
86.
ShaoYCornwellWXuK, et al.Chronic exposure to the combination of cigarette smoke and morphine decreases CD4(+) regulatory T cell numbers by reprogramming the Treg cell transcriptome. Front Immunol2022; 13: 887681.
87.
OkaSLeonJSakumiK, et al.MTH1 And OGG1 maintain a low level of 8-oxoguanine in Alzheimer's brain, and prevent the progression of Alzheimer's pathogenesis. Sci Rep2021; 11: 5819.
88.
MoriHYoshinoYIgaJI, et al.Aberrant expression of GABA-related genes in the hippocampus of 3xTg-AD model mice from the early to end stages of Alzheimer's disease. J Alzheimers Dis2023; 94: 177–188.
89.
PaysERadwanskaMMagezS. The pathogenesis of African Trypanosomiasis. Annu Rev Pathol2023; 18: 19–45.
90.
ChakrabortySTabriziZBhattNN, et al.A brief overview of neutrophils in neurological diseases. Biomolecules2023; 13: 743.
91.
SinghRKaurNDhingraN, et al.Protein misfolding, ER stress and chaperones: an approach to develop chaperone-based therapeutics for Alzheimer's disease. Int J Neurosci2023; 133: 714–734.
MontineTJMorrowJD. Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol2005; 166: 1283–1289.
94.
AlamJ. Vitamins: a nutritional intervention to modulate the Alzheimer's disease progression. Nutr Neurosci2022; 25: 945–962.
95.
GriggsETrageserKNaughtonS, et al.Recapitulation of pathophysiological features of AD in SARS-CoV-2-infected subjects. Elife2023; 12: e86333.
96.
ZhangLJuXChengY, et al.Identifying Tmem59 related gene regulatory network of mouse neural stem cell from a compendium of expression profiles. BMC Syst Biol2011; 5: 152.
97.
DuanTChuJHuF. Identification of peripheral blood GZMK (+) CD8 (+) T cells as biomarkers of Alzheimer's disease based on single-cell transcriptome. Sichuan Da Xue Xue Bao Yi Xue Ban2023; 54: 863–873.
98.
AskenaziMKavanaghTPiresG, et al.Compilation of reported protein changes in the brain in Alzheimer's disease. Nat Commun2023; 14: 4466.
99.
SongLChenJLoCZ, et al.Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer's disease. EBioMedicine2022; 82: 104175.
100.
MrdjenDFoxEJBukhariSA, et al.The basis of cellular and regional vulnerability in Alzheimer's disease. Acta Neuropathol2019; 138: 729–749.
101.
KoopmansFvan NieropPAndres-AlonsoM, et al.SynGO: an evidence-based, expert-curated knowledge base for the synapse. Neuron2019; 103: 217–234.e4.
102.
ShaoCYMirraSSSaitHB, et al.Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol2011; 122: 285–292.
103.
BaazaouiNIqbalK. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther2017; 9: 45.
104.
HanssonOKumarAJanelidzeS, et al.The genetic regulation of protein expression in cerebrospinal fluid. EMBO Mol Med2023; 15: e16359.
105.
BroderickLHoffmanHM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol2022; 18: 448–463.
106.
MrakREGriffinWS. Interleukin-1 and the immunogenetics of Alzheimer disease. J Neuropathol Exp Neurol2000; 59: 471–476.
107.
LiLIsmaelSNasoohiS, et al.Thioredoxin-interacting protein (TXNIP) associated NLRP3 inflammasome activation in human Alzheimer's disease brain. J Alzheimers Dis2019; 68: 255–265.
108.
SbaiODjelloulMAulettaA, et al.AGE-TXNIP axis drives inflammation in Alzheimer's by targeting Abeta to mitochondria in microglia. Cell Death Dis2022; 13: 302.
109.
KellerMRueggAWernerS, et al.Active caspase-1 is a regulator of unconventional protein secretion. Cell2008; 132: 818–831.
110.
LoreyMBRossiKEklundKK, et al.Global characterization of protein secretion from human macrophages following non-canonical caspase-4/5 inflammasome activation. Mol Cell Proteomics2017; 16: S187–S199.
111.
YangQNanayakkaraGKDrummerC, et al.Low-intensity ultrasound-induced anti-inflammatory effects are mediated by several new mechanisms including gene induction, immunosuppressor cell promotion, and enhancement of exosome biogenesis and docking. Front Physiol2017; 8: 818.
112.
ShaoYSaaoudFXuK, et al.Cardiovascular disease risk factors, immune checkpoints and Tregs. In: DjuricDMAgrawalDK (eds) Environmental factors in the pathogenesis of cardiovascular diseases. Advances in biochemistry in health and disease. Vol. 30. Cham: Springer, 2024, pp.51–93.
113.
ShenHWuNNanayakkaraG, et al.Co-signaling receptors regulate T-cell plasticity and immune tolerance. Front Biosci (Landmark Ed)2019; 24: 96–132.
114.
ShaoYYangWYNanayakkaraG, et al.Immune checkpoints are new therapeutic targets in regulating cardio-, and cerebro-vascular diseases and CD4(+)Foxp3(+) regulatory T cell immunosuppression. Int J Drug Discov Pharm2024; 3: 100022.
115.
KishiYKondoTXiaoS, et al.Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity. J Exp Med2016; 213: 2489–2501.
116.
AkintundeJKAkintolaTEAdenugaGO, et al.Naringin attenuates Bisphenol-A mediated neurotoxicity in hypertensive rats by abrogation of cerebral nucleotide depletion, oxidative damage and neuroinflammation. Neurotoxicology2020; 81: 18–33.
117.
YanJZuoGSherchanP, et al.CCR1 Activation promotes neuroinflammation through CCR1/TPR1/ERK1/2 signaling pathway after intracerebral hemorrhage in mice. Neurotherapeutics2020; 17: 1170–1183.
118.
MarangoniRGDattaPPaineA, et al.Thy-1 plays a pathogenic role and is a potential biomarker for skin fibrosis in scleroderma. JCI Insight2022; 7: e149426.
119.
YangJFangPYuD, et al.Chronic kidney disease induces inflammatory CD40+ monocyte differentiation via homocysteine elevation and DNA hypomethylation. Circ Res2016; 119: 1226–1241.
120.
Reed-GeaghanEGReedQWCramerPE, et al.Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci2010; 30: 15369–15373.
121.
FagensonAMXuKSaaoudF, et al.Liver ischemia reperfusion injury, enhanced by trained immunity, is attenuated in caspase 1/caspase 11 double gene knockout mice. Pathogens2020; 9: 879.
122.
BreuerKForoushaniAKLairdMR, et al.InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res2013; 41: D1228–D1233.
123.
CaoYDongQWangD, et al.TIDB: a comprehensive database of trained immunity. Database (Oxford)2021; 2021: baab041.
124.
LuYSunYDrummerC, et al.Increased acetylation of H3K14 in the genomic regions that encode trained immunity enzymes in lysophosphatidylcholine-activated human aortic endothelial cells - Novel qualification markers for chronic disease risk factors and conditional DAMPs. Redox Biol2019; 24: 101221.
125.
CaligiuriG. Mechanotransduction, immunoregulation, and metabolic functions of CD31 in cardiovascular pathophysiology. Cardiovasc Res2019; 115: 1425–1434.
126.
ArtyomovMNVan den BosscheJ. Immunometabolism in the single-cell era. Cell Metab2020; 32: 710–725.
127.
Yvan-CharvetLBonacinaFGuinamardRR, et al.Immunometabolic function of cholesterol in cardiovascular disease and beyond. Cardiovasc Res2019; 115: 1393–1407.
128.
SunYLuYLiuL, et al.Caspase-4/11 promotes hyperlipidemia and chronic kidney disease-accelerated vascular inflammation by enhancing trained immunity. JCI Insight2024; 9: e177229.
129.
Trejo-LopezJAYachnisATProkopS. Neuropathology of Alzheimer's disease. Neurotherapeutics2022; 19: 173–185.
130.
DeTureMADicksonDW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener2019; 14: 32.
131.
LuegGGrossCCLohmannH, et al.Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging2015; 36: 81–89.
132.
HenekaMTKummerMPStutzA, et al.NLRP3 Is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature2013; 493: 674–678.
133.
de Brito ToscanoECRochaNPLopesBNA, et al.Neuroinflammation in Alzheimer's disease: focus on NLRP1 and NLRP3 inflammasomes. Curr Protein Pept Sci2021; 22: 584–598.
134.
McManusRMLatzE. NLRP3 Inflammasome signalling in Alzheimer's disease. Neuropharmacology2024; 252: 109941.
135.
TaipaRdas NevesSPSousaAL, et al.Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiol Aging2019; 76: 125–132.
136.
NordengenKKirsebomBEHenjumK, et al.Glial activation and inflammation along the Alzheimer's disease continuum. J Neuroinflammation2019; 16: 46.
137.
RekateHL. A consensus on the classification of hydrocephalus: its utility in the assessment of abnormalities of cerebrospinal fluid dynamics. Childs Nerv Syst2011; 27: 1535–1541.
138.
WichmannTODamkierHHPedersenM. A brief overview of the cerebrospinal fluid system and its implications for brain and spinal cord diseases. Front Hum Neurosci2021; 15: 737217.
139.
da Silva-ButtkusPSpielmannNKlein-RodewaldT, et al.Knockout mouse models as a resource for the study of rare diseases. Mamm Genome2023; 34: 244–261.
140.
GurumurthyCBSaundersTLOhtsukaM. Designing and generating a mouse model: frequently asked questions. J Biomed Res2021; 35: 76–90.
141.
ApgarTLSandersCR. Compendium of causative genes and their encoded proteins for common monogenic disorders. Protein Sci2022; 31: 75–91.
142.
SterniczukRAntleMCLaFerlaFM, et al.Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res2010; 1348: 149–155.
